{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:37:15Z","timestamp":1793187435628,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare autoimmune disorder that affects the neuromuscular junction, with a global prevalence of approximately 30 cases per 100,000 individuals. Although dysphagia occurs as an initial symptom in 6%\u201315% of patients, isolated dysphagia as the sole presenting and predominant manifestation is exceedingly rare, posing a significant diagnostic challenge. Furthermore, a complex bidirectional relationship exists between dysphagia and psychiatric conditions such as anxiety and depression, which often leads to misdiagnosis. Approximately 20% of patients with MG are refractory to conventional immunosuppressive therapy. The novel FcRn antagonist efgartigimod rapidly and sustainably reduces pathogenic IgG levels, providing a new therapeutic option for refractory generalized MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 33-year-old previously healthy woman presented with fluctuating dysphagia and a sensation of a pharyngeal foreign body, exhibiting diurnal variation characterized by improvement in the morning and worsening in the evening. Symptom onset coincided with a family quarrel and subsequently intensified after an upper respiratory tract infection. Multiple laryngoscopies, gastrointestinal endoscopies, and brain magnetic resonance imaging (MRI) revealed no abnormalities. Initially misdiagnosed with an anxiety-depressive disorder, she experienced only partial and transient improvement with citalopram. Two subsequent acute exacerbations triggered by infections led to a complete inability to swallow. Neurological examination indicated dysarthria, choking when drinking, and mild distal limb weakness, assessed at 4+\/5 on the Medical Research Council scale. The neostigmine test yielded a strong positive result, and serum anti-acetylcholine receptor (AChR) antibodies were detected at a titer of 1:10, while repetitive nerve stimulation (RNS) remained normal. Chest computed tomography (CT) revealed no thymoma. The patient was diagnosed with moderate generalized MG characterized by AChR-antibody positivity and classified as MGFA class IIIb. Following the failure of initial immunosuppressive therapy, which included prednisone at 30 mg daily, pyridostigmine at 60 mg three times daily, and azathioprine at 25 mg daily, the patient underwent two cycles (totaling 8 infusions) of the FcRn antagonist efgartigimod. Marked improvement in dysphagia was observed, as evidenced by a decrease in the MG-Activities of Daily Living (MG-ADL) score from 8 to 2 and a reduction in the Quantitative Myasthenia Gravis (QMG) score from 10 to 1. At the 6-month follow-up, the patient achieved complete clinical remission, with both MG-ADL and QMG scores reaching 0, and attained minimal manifestation status, while prednisone was tapered to 5 mg daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case indicates that isolated fluctuating dysphagia warrants consideration of MG, even in the presence of psychosocial stressors or partial response to psychiatric medications. A negative RNS does not exclude MG, especially in bulbar-onset cases. Clinicians should prioritize organic etiologies and perform neostigmine and anti-AChR testing to avoid delayed diagnosis. Furthermore, efgartigimod is effective for refractory bulbar MG, enabling rapid remission and corticosteroid tapering.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1751111","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:16Z","timestamp":1783661896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Myasthenia gravis with dysphagia as the first symptom and misdiagnosed as anxiety-depressive state: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Kariman","family":"Aili","sequence":"first","affiliation":[{"name":"Neuroimmunology Department, Neurology Diagnosis and Treatment Center, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]},{"name":"Xinjiang Clinical Research Center for Stroke and Neurological Rare Disease","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayinuer","family":"Maimaiti","sequence":"additional","affiliation":[{"name":"Neuroimmunology Department, Neurology Diagnosis and Treatment Center, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]},{"name":"Xinjiang Clinical Research Center for Stroke and Neurological Rare Disease","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic literature review","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59104","article-title":"Advances in understanding and managing myasthenia gravis: current trends and future directions","volume":"16","author":"Jaiswal","year":"2024","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S146617","article-title":"Familial aggregation of myasthenia gravis in affected families: a population-based study","volume":"9","author":"Liu","year":"2017","journal-title":"Clin Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12883-024-03869-9","article-title":"Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries","volume":"24","author":"Pesa","year":"2024","journal-title":"BMC Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3109\/00016485909129208","article-title":"Dysphagia and dysarthria in myasthenia gravis","volume":"50","author":"Walander","year":"1959","journal-title":"Acta Oto-Laryngologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-001-0114-4","article-title":"A prospective assessment of the characteristics of dysphagia in myasthenia gravis","volume":"17","author":"Colton-Hudson","year":"2002","journal-title":"Dysphagia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v12.i3.470","article-title":"Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients","volume":"12","author":"Yu","year":"2022","journal-title":"World J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20193426","article-title":"Psychopharmacology in myasthenia gravis patients with focus on depression","volume":"7","author":"Wardhana","year":"2019","journal-title":"Int J Res Med Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-024-10770-7","article-title":"Association between dysphagia and depressive symptoms: propensity score matching approaches","volume":"40","author":"Yoo","year":"2025","journal-title":"Dysphagia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/lary.31164","article-title":"Correlations between anxiety and\/or depression diagnoses and dysphagia severity","volume":"134","author":"Doruk","year":"2024","journal-title":"Laryngoscope"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3928\/0048-5713-20020901-06","article-title":"The PHQ-9: a new depression diagnostic and severity measure","volume":"32","author":"Kroenke","year":"2002","journal-title":"Psychiatr Ann"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis-specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2011000200006","article-title":"Psychiatric disorders in myasthenia gravis","volume":"69","author":"Ybarra","year":"2011","journal-title":"Arq Neuro-Psiquiatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010056","article-title":"Depression: a contributing factor to the clinical course in myasthenia gravis patients","volume":"60","author":"Mihalache","year":"2024","journal-title":"Medicina"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09767-7","article-title":"Depression in myasthenia gravis: a heterogeneous and intriguing entity","volume":"267","author":"Gavrilov","year":"2020","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2026.1791340","article-title":"Myasthenia gravis and anxiety-depression states: an integrated clinical and Mendelian randomization study","volume":"17","author":"Luo","year":"2026","journal-title":"Front Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.136.1.92","article-title":"Myasthenia gravis\u2014the difficult diagnosis","volume":"136","author":"Sneddon","year":"1980","journal-title":"Br J Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721060-00004","article-title":"Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment","volume":"21","author":"Kulaksizoglu","year":"2007","journal-title":"CNS Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14773","article-title":"Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: an estimation of risk based on reporting frequency","volume":"28","author":"Trillenberg","year":"2021","journal-title":"Eur J Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-977x(05)80869-7","article-title":"Citalopram treatment of depression in myasthenia gravis patients: an open study","volume":"15","author":"Kulaksizoglu","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25214","article-title":"Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis","volume":"55","author":"Abraham","year":"2017","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2468\u201376","DOI":"10.4103\/1673-5374.363824","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","author":"Zhu","year":"2022","journal-title":"Neural Regener Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1986.tb112345.x","article-title":"Myasthenia gravis: the problem of a \u201cpsychiatric\u201d misdiagnosis","volume":"144","author":"Nicholson","year":"1986","journal-title":"Med J Aust"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08240-5","article-title":"Delayed diagnosis of myasthenia gravis caused by concurrent anxiety symptoms","volume":"46","author":"Gasparini","year":"2025","journal-title":"Neurol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1038\/s41598-025-91470-6","article-title":"Unusual presentations of myasthenia gravis and misdiagnosis","volume":"15","author":"Oguz-Akarsu","year":"2025","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210780","article-title":"Assessing the rate and causes of myasthenia gravis misdiagnosis","volume":"104","author":"Falso","year":"2024","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1055\/s-0046-1817045","article-title":"Isolated dysphagia masking myasthenia gravis diagnosis","volume":"84","author":"Lusvarghi","year":"2026","journal-title":"Arq Neuropsiquiatr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:17Z","timestamp":1783661897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1751111"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1751111","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1751111"}}